Meconium aspiration may cause mechanical obstruction of airways (1, 2) , inactivate surfactant (3-7), induce pulmonary hypertension (8, 9) , and trigger inflammation (8, 10, 11) .
Regarding cause of inflammation in MAS, various factors have been proposed. For instance, bile acids (7, 12) and FFA (13) in meconium may induce chemical pneumonitis. Endothelial microvascular damage (1) and inflammation (14) have been observed 6 h after meconium insufflation. Further, an increased neutrophil count and chemotactic activity have been detected in tracheal aspirate 12 h after instillation of meconium (15) .
There is evidence of a favorable effect of glucocorticoids on lung physiologic parameters in MAS (14) . Meconium may stimulate chemotaxis through its content of IL-8 (16) , influence oxidative burst (17, 18) , and increase activity of phospholipase A 2 (5) , which catalyzes formation of eicosanoids. Finally, meconium may stimulate macrophages to produce tumor necrosis factor (19) , nitric oxide (20) , and superoxide anion (21) .
Meconium contains surfactant inhibitors like FFA (3, 4, 22) , bilirubin (7) , and enzymes (5) . In vitro, meconium inhibits surfactant even at low concentrations (6, 23) . Albumin may also inhibit surfactant. The mechanism of surfactant inhibition by albumin (24 -26) and FFA (19, 27 ) is claimed to be through biophysical interaction due to intrinsic surface activity. Enzymes in meconium inactivate surfactant by hydrolyzing its active agent dipalmitoylphosphatidylcholine (5) to lysophosphatidylcholine. Excessively, lysophosphatidylcholine inhibits surfactant (28) .
We have recently shown that albumin attenuates pulmonary dysfunction in experimental MAS when it is mixed with meconium before instillation (29) . This may be due to the high binding affinity of albumin for fatty acids and bilirubin (30) . Additionally, the increase of IL-8 in the animals instilled with PIP and the fraction of inspired oxygen (FiO 2 ) from 8% to 21% for the first 10 min of the reoxygenation period. Later on, the ventilator settings were adjusted as needed to keep SaO 2 Ͼ85% and PCO 2 in the range of 4 -6 kPa. Maximum ventilator settings were as follows: rate, 60/min; FiO 2 , 90%; and PIP, 45 cm H 2 O.
The ventilator monitored lung function. Mean airway pressure was measured at the Y-piece and lung volumes calculated as a function of flow. Dynamic compliance (C dyn ) and resistance (R), and their product, the time constant (Tc), were calculated with aid of a computer program (Drägerwerk AG, Lübeck, Germany) integrated in the ventilator. OI was calculated according to the following formula: OI ϭ (MAP ϫ FiO 2 )/(PaO 2 ϫ 7.5), where MAP ϭ mean airway pressure (mbar) and PaO 2 was measured in kilopascals. VI was calculated according to the following formula: VI ϭ (PaCO 2 ϫ 7.5 ϫ F ϫ PIP)/1000, where PaCO 2 was measured in kilopascals, F ϭ frequency of ventilation/minute, and PIP ϭ peak inspiratory pressure (mbar).
Sampling. Arterial blood gas tensions and base excess were determined on 0.2 mL samples withdrawn from the femoral artery and analyzed (CibaCorning blood gas analyzer 860; Bayer HealthCare Diagnostics Division, Tarrytown, NY). Samples were taken during surgery, at baseline, during hypoxia, at 10, 20, 30, 60, and 90 min of reoxygenation, and then every hour until 8 h of reoxygenation. The catheter in the femoral artery was continuously flushed with heparin (2 IU/mL) 3 mL/h. The Hb level was measured at the start and end of the experiment (Ciba-Corning 279 Co-oximeter; Bayer HealthCare Diagnostics Division). The total withdrawal of blood volume was Ͻ10% of the total blood volume.
Tracheal aspirations (TA) were done on four occasions during every experiment, with great care to avoid the stress it might cause as far as lung function and blood pressure are concerned. After instillation of 2 mL saline in the trachea, aspiration was performed with a maximum suction pressure of 20 kPa, followed by hand ventilation for 30 s. After centrifugation (3000 rpm for 5 min), supernatant was preserved in Ϫ24°C and thawed for IL-8 (ELISA kit, swine; BioSource International, Camarillo, CA) and protein analyses (BCA protein assay kit; Pierce Biotechnology, Inc., Rockford, IL).
Statistics. To visualize the variability, the mean value for all continuous values are given with 95% confidence interval (CI). For intra-or intergroup comparisons of maximum two measurements, 95% CI was used. Delta values were used to correct for differences between animals at baseline, and start of hypoxia (H 0 ) was chosen as baseline. Due to lack of normal distribution, VI and OI were log transformed for testing of differences between the groups. ANOVA was used to compare groups whenever more than two measurements for each piglet were compared. Outcome (dependent) variables were lung compliance, OI, VI, PAP, CO, and LAP. Predictor (explanatory) variables were time, albumin versus saline, and meconium versus controls. Pearson correlation coefficients were estimated to model the linear relationship between variables. Bonferroni correction was chosen as posthoc test. Rejection probability in hypothesis testing was set to 5%.
Ethics. The Norwegian Animal Experimental Board approved the experimental protocol. (Table 1) . After meconium instillation, PAP was significantly higher in MAS II animals (540 mg/kg) compared with control animals (p Ͻ 0.005) ( Table 1 ). There were no differences in LAP or CVP. No differences were observed comparing saline as rescue therapy versus albumin in any of the hemodynamic variables (data not shown).
RESULTS

Hemodynamics. CO decreased and PAP increased during hypoxia in MAS as well as in control animals
Oxygenation and ventilation. In MAS animals with the highest meconium dose (MAS I ϭ 675 mg/kg), an increase was observed in OI from 1.4 Ϯ 0.1 (baseline) to 12.8 Ϯ 1.8 (mean Ϯ CI for all time points after instillation of meconium), with a maximum (25.4 Ϯ 3.4) at 6 h ( Fig. 1) . In MAS animals with the lower meconium dose (MAS II ϭ 540 mg/kg), an increase was observed in OI from 1.4 Ϯ 0.1 (baseline) to 7.3 Ϯ 1.2 (mean Ϯ CI for all time points after instillation of meconium), with a maximum (12 Ϯ 2.8) at 5 h after instillation of meconium ( Fig. 1) . For the first 10 min of reoxygenation, OI increased equally in all groups, including controls (p Ͻ 0.001, Table 2) .
The development of VI was almost identical to OI in both MAS animals and control animals. In MAS I animals, an increase was observed in VI from 18.7 Ϯ 2.6 (baseline) to 66.7 Ϯ 6.6 (mean Ϯ CI for all time points after instillation of meconium), with a maximum (96 Ϯ 19.0) at 6 h after instillation of meconium (Fig. 1) . In MAS II animals, an increase was observed in VI from 16.2 Ϯ 1.6 (baseline) to 44.9 Ϯ 3.6 (mean Ϯ CI for all time points after instillation of meconium), with a maximum (64 Ϯ 19.4) at 5 h after instillation of meconium (Fig. 1) . After 60 min, VI was higher (p Ͻ 0.05) in MAS animals compared with control animals (Fig. 1) . PaCO 2 tended correspondingly toward higher values in MAS animals versus controls (Table 2) .
No difference was observed comparing VI or OI in MAS animals receiving saline as rescue therapy versus albumin (VI, p ϭ 0.36; OI, p ϭ 0.38).
Compliance. Compliance (mL/mbar) was reduced (46 -60%) in all MAS animals and reached a minimum value at 4 h reoxygenation (Fig. 2) . In the control animals, compliance decreased during hypoxia, but thereafter increased and almost reached baseline values during reoxygenation (Fig. 2) . Compliance decreased more in MAS I piglets (meconium ϩ saline: Ϫ1.4 Ϯ 0.38, meconium ϩ albumin: Ϫ1.2 Ϯ 0.52) compared with MAS II (meconium ϩ saline: Ϫ1.0 Ϯ 0.38, meconium ϩ albumin: Ϫ0.76 Ϯ 0.24) (Fig. 2) . Even though the differences were small, dynamic lung compliance was significantly higher if meconium instillation was followed by albumin instillation rather than saline instillation irrespective of dose of meconium (MAS I, p ϭ 0.008; MAS II, p ϭ 0.002). These differences, however, did not reach significance if changes from start of reoxygenation, R 0 (data not shown), were calculated instead of changes from stabilization period following surgery.
IL-8. IL-8 increased (p Ͻ 0.001) in all MAS animals (Fig. 3) . In MAS I animals (675 mg/kg), a 10-fold increase was observed from baseline (1 Ϯ 0.4 g/mL) to maximum (10 Ϯ 1.7 g/mL) at 4 h after instillation of meconium (Fig. 3) . In MAS II animals (540 mg/kg), a 5-fold increase was observed from baseline (2 Ϯ 0.7 g/mL) to maximum (10 Ϯ 1.3 g/mL) (Fig. 3 ) at 8 h after instillation of meconium. By contrast, tracheal proteins increased only 112% (MAS I) and 58% (MASII) (Fig. 3) , respectively. The increase in IL-8 correlated with deterioration of lung function [MAS I-OI: r ϭ 0.71, p Ͻ 0.0001; VI: r ϭ 0.71, p Ͻ 0.0001; compliance: r ϭ Ϫ0.66, p Ͻ 0.0001 (Fig. 4) ; and MAS II-OI: r ϭ 0.49, p ϭ 0.0002; VI: r ϭ 0.66, p Ͻ 0.0001; compliance: r ϭ Ϫ0.59, p Ͻ 0.0001 (Fig. 5) ]. In the control animals, nonsignificant increases of IL-8 (18%) and protein (16%) were observed from baseline to culmination (Fig. 3) . In the control animals, no correlations between IL-8 and lung function (OI, VI, and compliance) were observed (data not shown). Finally, we observed no difference in MAS animals receiving saline as rescue therapy versus albumin (data not shown).
DISCUSSION
We observed a significant increase of IL-8 in piglet lungs after instillation of meconium. The IL-8 increase correlated Experimental animals: meconium ϩ saline/albumin [MAS I ϭ 675 mg dry weight human meconium/kg piglet, n ϭ 12 (saline ϩ albumin instilled); MAS II ϭ 540 mg/kg, n ϭ 14 (saline ϩ albumin instilled)]. Control animals: saline ϩ albumin, n ϭ 4; H 0 , start of hypoxia; CVP, central venous pressure (mm Hg); CO, cardiac output (mL/min). Data are mean Ϯ 95% CI.
* p Ͻ 0.05, MAS vs controls. with a significant deterioration of lung function. Mortality and morbidity were related to the amount of meconium instilled. Dynamic lung compliance in piglets with MAS was higher if albumin was instilled as rescue therapy versus saline. In spite of the use of high doses of meconium, there was no evidence for an early obstructing phase in our experiment, which may be due to reduction of the particle size of this meconium below the point of producing obstruction. It has been documented that the chemotactic activity of meconium on neutrophils may be caused by IL-8 (32) present in meconium (16) . Our data indicate de novo synthesis of IL-8 in MAS animals, in accordance with an earlier study in our group on piglets (31) executed with lower doses of meconium (330 mg/kg). As opposed to the study of Tollofsrud et al. (31) , we found a highly significant correlation between IL-8 and deterioration of oxygenation, ventilation, and compliance. However, we did not reproduce significant differences in IL-8 between albumin-and saline-treated MAS animals as shown by Tollofsrud et al. (31) . Inasmuch as IL-8 is known to be produced in acute inflammation (33) , the increase of IL-8 simultaneously to deterioration of lung function raises the possibility that meconium triggers lung inflammation within the first hours after instillation, and, further, this inflammation may cause reduction of oxygenation, ventilation, and compliance.
Because harvesting specific lung proteins, e.g. cytokines, by tracheal aspiration may be suboptimal as an estimate of the actual level of these proteins, we also analyzed for total protein content in tracheal aspirates. The increases of IL-8 exceeded that of total protein, which may be due to inflammation caused by meconium. Local production of IL-8 may cause lung damage through chemotaxis on neutrophile granulocytes.
IL-8 has been documented in cord blood of premature newborns (34) in levels clearly below what we measured in the lungs. Our results indicate local production in the lungs only and do not permit any conclusions regarding systemic level of IL-8. Nevertheless, it seems reasonable that levels of cytokines in the lung should exceed blood levels provided lung inflammation.
Lung inflammation and local IL-8 production might be due to volu-and barotraumas (35) . The insufflation pressures in the animals aspirated with meconium had to be much higher to achieve the same tidal volume as control animals. On the other hand, it may be tidal volume rather than insufflation pressure that is of concern (36, 37) . In fact, in comparing meconium animals to controls, our tidal volumes were not different, and, therefore, our data may indicate IL-8 production in the lungs due to inflammation caused by meconium.
The main determinants of dynamic lung compliance are surfactant and the elastic components of lung tissue (38) . Several in vitro studies indicate that both albumin (24 -26, 39 -42) and meconium (4 -6,23,43) inhibit surfactant, so one might expect an additive inhibition of surfactant when combining albumin and meconium in vivo. Provided a lack of influence on the elastic components, surfactant inhibition should reduce compliance. On the contrary, we found an increase rather than reduction in dynamic lung compliance in the piglets receiving both meconium and albumin compared with those receiving meconium and saline. Our findings are in agreement with previous in vivo studies from our group show- ing that adding albumin to meconium before instilling it as an intratracheal bolus reduces pulmonary insufficiency (29) . Albumin may inactivate surfactant inhibitors in meconium by binding them (26, 29) , and further it is conceivable that an interaction between albumin and other surfactant inhibitors in meconium abolishes the potential inhibition of albumin, as well. In fact, this has been shown in vitro by combining albumin with arachidonic acid, palmitoleic acid, and oleic acid (26) , all major FFA in meconium binding to albumin. In the same study, an additive inhibition was shown when combining albumin with phospholipids, which do not bind to albumin. This provides encouragement to the view that the effect of albumin on compliance could be independent of the way FFA in meconium might inhibit surfactant. We may speculate that albumin could influence other determinants of dynamic compliance like the elastic components, by for instance reducing edema through osmotic mechanisms or by a mucokinetic effect (44) on meconium by reducing its viscosity. Lung compliance could thereby be improved by increasing clearance of meconium from the airways.
We have not reproduced such lowering of OI, VI, and IL-8 in the albumin groups compared with the previous studies of Tollofsrud et al. (29, 31) . However, there were major differences in the experimental protocols. The experiments share in common the stoichiometric relationship between measured FFA in the meconium pool and albumin instilled, but the effective dose of albumin in our study must be expected to be lower inasmuch as it was instilled sequentially to meconium and not simultaneously. Further, our study was with high doses of meconium, motivated by a wish to induce a disturbance in lung function comparative to that seen in infants requiring respiratory support. In fact, we used 97% (MAS I ϭ 675 mg/kg) and 58% (MAS II ϭ 540 mg/kg) higher doses of meconium, respectively. Retrospectively, a higher albumin dose and volume should have been used, considering the enormous surface area of the lung and possible accumulation of albumin proximal to meconium in the lungs.
Several in vitro studies on surfactant inactivation have demonstrated the importance of the relative surfactant concentration to inhibitor concentrations (6, 22, 23) . This balance could in our experiments have been displaced compared with those seen in the study of Tollofsrud et al. (29) . Moreover, our high-dose model leads to more serious detrimental effect on the lungs and may trigger systemic pathophysiological mechanisms like systemic inflammatory response syndrome. Serum protein leakage (42) to alveoli may be one aspect in a systemic disease and has been shown to exist already 1 h after meconium instillation in doses analogous to the study of Tollofsrud et al. (29) . It has been proposed that plasma proteins leaking into the alveolus during lung edema and hemorrhage inhibit surfactant activity by biophysical mechanisms (41) .
In conclusion, we have shown higher lung compliance in MAS by adding albumin after instillation of meconium. This may be due to inhibition of surfactant inhibitors in meconium by albumin, an effect possibly exceeding the surfactant inhibition of albumin. Further, we saw no early obstructing phase, but rather a rapid deterioration 2-3 h after instillation of meconium in the animals that seemed to be triggered to serious illness or death. A significant increase in lung IL-8 was observed simultaneously to deterioration of lung function in MAS animals. The mechanisms causing this phase must be further investigated.
